摘要
目的利用表面增强激光解吸电离飞行时间质谱（surface-enhanced laser desorption ionizationtime-of-flight mass spectrometry，SELDI-TOF-MS）技术研究慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）血清蛋白质指纹图谱。方法应用SELDI-TOF-MS技术检测30例COPD患者和18名健康人血清蛋白质质谱，筛选出COPD血清差异蛋白。结果COPD患者血清蛋白图谱与对照组相比，存在25个差异表达蛋白（P〈0．05），包括9个高表达蛋白，其中质荷比为2152、3287、3533、3614、4924、5887、6729的7个蛋白质其含量由对照组、COPD稳定期、COPD急性加重期依次升高（P〈0．05）；16个低表达蛋白，其中质荷比为4313、4380、8634、8765、8842、13878、14086的7个蛋白质其含量由对照组、COPD稳定期、COPD急性加重期依次升高（P〈0．05）。经蛋白质数据库搜索，初步确立特定相对分子质量所对应的蛋白。结论SELDI-TOF-MS技术为研究COPD提供了可行的技术平台，COPD患者血清和对照组血清中存在明显差异蛋白，这些差异蛋白可能与COPD的发生发展密切相关。
Objective To establish serum protein fingerprint profile in patients with chronic obstructive pulmonary disease （COPD） by using surface-enhanced laser desorption ionizationtime-of-flight mass spectrometry （SELDI-TOF-MS） technique. Methods Serum samples of 30 COPD patients and 20 healthy persons were analyzed by SELDI-TOF-MS to select the differently expressed proteins. Results Compared with normal control, 25 protein biomarkers were identified. Among them, 9 proteins were upregulated. The intensity of the 7 significant expressive proteins from COPD with m/z value of 2 152,3 287, 3 533,3 614, 4 924, 5 887, 6 729 was orderly increasing from control, stable phase of COPD to acute exacerbation COPD（ P 〈0.05）. Sixteen proteins were down-regulated. The intensity of the 7 significant expressive proteins from COPD with m/z value of 4 313,4 380,8 634,8 765,8 842, 13 878, 14 086 was orderly reducing from control, stable phase of COPD to acute exacerbation COPD （P〈0.05）. These proteins were confirmed by searching database. Conclusions SELDI-TOF-MS is a useful tool for the study of COPD. There are obvious differentially expressed proteins in COPD and controls,which may have close relationship with the genesis and development of COPD.
出处
《国际呼吸杂志》
2009年第7期410-413,共4页
International Journal of Respiration
关键词
慢性阻塞性肺疾病
表面增强激光解析电离飞行时间质谱
蛋白质组学
Chronic obstructive pulmonary disease
Surface-enhanced laser desorption ionization timeof-flight mass spectrometry
Proteomics
